Bibliothek

feed icon rss

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    Digitale Medien
    Digitale Medien
    Springer
    Journal of neurology 232 (1985), S. 24-28 
    ISSN: 1432-1459
    Schlagwort(e): Parkinsonism ; Mesulergine ; Dopamine agonist ; Long-term effects
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Summary In 15 patients (8 men, 7 women), aged 44–81 years, with idiopathic parkinsonism, the effects of mesulergine (CU 32-085) were observed for up to 3 years. Of these patients, four had been without previous levodopa treatment, five had been on levodopa/decarboxylase inhibitor for 6.4 years and six patients had been on levodopa/decarboxylase inhibitor and bromocriptine for a period of 7.5 years. Mesulergine proved to be effective in all three groups of patients and for each main symptom of the disease. Rigidity and tremor showed a better response than akinesia. A decline in efficacy could be observed after 18 months of treatment. By increasing the levodopa dosage, the worsening of the symptomatology could be reduced again and after 3 years patients were slightly better off than before the introduction of mesulergine. Fine motor performance showed a longer-lasting improvement than walking, which was affected by an increase of freezing. Mesulergine was not fully sufficient when given in monotherapy and the levodopa saving effect was only temporary. Parallel with the decline in the therapeutic response as assessed by the rating scales, there was a worsening in the on/off symptomatology. The on/off symptoms, evaluated by patients themselves, had shown very small or no improvement at the beginning of mesulergine administration, contrasting with the findings reflected in the assessment scales. The most frequent side-effects were hallucinations and dyskinesias. Orthostatic hypotension did not prove a problem. Dyskinesias were not seen during monotherapy with mesulergine in de novo patients.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    Digitale Medien
    Digitale Medien
    Springer
    Journal of neural transmission 5 (1993), S. 67-75 
    ISSN: 1435-1463
    Schlagwort(e): Glutamate ; excitatory neurotransmitter ; lamotrigine ; Parkinson's disease ; basal ganglia pathways
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Summary Recent experiments provide evidence that the NMDA-antagonist MK-801 has a locomotor-stimulating effect in monoamine-depleted rodents. These findings are based upon a hypothetical pathway-circuit including the basal ganglia as a model reflecting hypo- and hyperkinetic movement disorders. We have treated 5 patients suffering from Parkinson's disease with the antiepileptic drug “lamotrigine” which does not appear to be an NMDA-antagonist but acts functionally as a glutamate antagonist by inhibition of presynaptic glutamate release.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 3
    Digitale Medien
    Digitale Medien
    Springer
    European archives of psychiatry and clinical neuroscience 218 (1974), S. 125-140 
    ISSN: 1433-8491
    Schlagwort(e): Parkinsonism ; Levodopa ; Factor Analytic Concept of Intelligence ; Stability of General Intelligence ; Parkinson-Syndrom ; l-Dopa ; Faktorenanalytisches Intelligenzkonzept ; Stabilität der allgemeinen Intelligenz
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Beschreibung / Inhaltsverzeichnis: Zusammenfassung Das Verhalten der allgemeinen Intelligenz von 74 Parkinson-Patienten wurde vor und während einer l-Dopa-Therapie untersucht. Dazu wurden Standardintelligenztests, eine klinisch-neurologische Beurteilung der hirnorganischen Leistungsfähigkeit und eine Selbsteinschätzung von Gedächtnis und Denkfähigkeit durch die Patienten herangezogen. Ausgangspunkt war ein faktorenanalytisches Konzept, in dem die allgemeine Intelligenz durch zwei Faktoren zweiter Ordnung darstellbar wird. Die gefundenen insignifikanten Mittelwertdifferenzen im Verlauf bedeuten, daß die allgemeine Intelligenz in ihren beiden Komponenten während der Therapie praktisch keine Veränderung erfährt. Abweichende Befunde der Literatur betreflten Änderungen von Teilkomponenten der Intelligenz, nicht aber der allgemeinen Intelligenz im Sinne des zugrundegelegten Konzeptes.
    Notizen: Summary We investigated features of the general intelligence of 74 patients with Parkinson's disease before and during Levodopa Therapy. The variables used were standardized intelligence tests, neurological ratings of brain performance and patients' self-ratings of memory and thinking ability. We used a factor analytic concept defining general intelligence in the form of two second order factors. The changes in means were insignificant. The conclusion was that both components of general intelligence remain stable during this therapy. Discrepancies between our results and those obtained by other authors who have used intelligence tests are discussed; they seem to have recorded changes in part components (primary factors) rather than general intelligence.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 4
    Digitale Medien
    Digitale Medien
    Springer
    Journal of neural transmission 10 (1995), S. 199-206 
    ISSN: 1435-1463
    Schlagwort(e): Glutamate ; glutamate release ; antiglutamatergic activity ; excitatory neurotransmitter ; Lamotrigine ; Parkinson's disease ; basal ganglia ; neurotransmission ; therapy
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Summary Antiglutamatergic acting substances are considered to be useful tools for the treatment of hypokinesia in animal models for Parkinson's disease (PD). Moreover, most known antiglutamatergic compounds act postsynaptically and are either toxic or weak with regard to their clinical potency. The antiepileptic drug “Lamotrigine (LTG)” inhibits presynaptic glutamate release and may therefore provide a novel approach for PD therapy. Encouraging results from a pilot project led us to establish a placebo controlled trial including 20 patients with PD. The substance was generally well tolerated. There was a significant difference in the investigator's overall assessment of efficacy (6/10 vs. 2/10 improvement; p〈0.05) and a tendency for LTG to exhibit a beneficial effect in some registration parameters, but no significant differences in motor response were found between the two groups. We failed to confirm that LTG mediates a strong antiparkinsonian effect in this small study, but to clearly demonstrate slight or moderate beneficial effects larger groups are required.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...